Y Ichinose

Summary

Affiliation: National Kyushu Cancer Center
Country: Japan

Publications

  1. ncbi request reprint [Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer]
    Hiroshi Wataya
    Dept of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Gan To Kagaku Ryoho 33:194-6. 2006
  2. doi request reprint S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Thorac Oncol 6:2069-75. 2011
  3. pmc Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial
    T Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame, Fukuoka 811 1395, Japan
    Br J Cancer 95:717-21. 2006
  4. doi request reprint Phase I study of topotecan and cisplatin in patients with small cell lung cancer
    Yukito Ichinose
    National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 41:197-203. 2011
  5. ncbi request reprint Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Natl Cancer Inst 95:605-10. 2003
  6. ncbi request reprint Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka, Japan
    Clin Cancer Res 10:4369-73. 2004
  7. pmc UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Y Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    Br J Cancer 93:770-3. 2005
  8. ncbi request reprint Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Surg 76:1810-4; discussion 1815. 2003
  9. doi request reprint Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy
    Yukito Ichinose
    National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 40:521-9. 2010
  10. ncbi request reprint A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical inter
    Yukito Ichinose
    National Kyushu Cancer Center, Fukuoka National Cancer Center Hospital, Tokyo, Japan
    J Thorac Cardiovasc Surg 123:695-9. 2002

Collaborators

Detail Information

Publications82

  1. ncbi request reprint [Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer]
    Hiroshi Wataya
    Dept of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Gan To Kagaku Ryoho 33:194-6. 2006
    ..Adverse events of the combination chemotherapy were milder than other combination chemotherapy described before. Therefore, S-1 plus CDDP combination chemotherapy is a future candidate for phase III clinical study...
  2. doi request reprint S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Thorac Oncol 6:2069-75. 2011
    ..To evaluate the combination chemotherapy using oral antimetabolite S-1 plus cisplatin (SP) with concurrent thoracic radiotherapy (RT) followed by the consolidation SP for locally advanced non-small cell lung cancer...
  3. pmc Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial
    T Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame, Fukuoka 811 1395, Japan
    Br J Cancer 95:717-21. 2006
    ..The median survival time of all patients was 239 days. Hypotonic cisplatin treatment for malignant pleural effusion of NSCLC is therefore considered to be feasible and effective. A phase III study of HPT is thus warranted...
  4. doi request reprint Phase I study of topotecan and cisplatin in patients with small cell lung cancer
    Yukito Ichinose
    National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 41:197-203. 2011
    ..This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study...
  5. ncbi request reprint Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Natl Cancer Inst 95:605-10. 2003
    ....
  6. ncbi request reprint Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka, Japan
    Clin Cancer Res 10:4369-73. 2004
    ..To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients...
  7. pmc UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Y Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    Br J Cancer 93:770-3. 2005
    ..This combination chemotherapy demonstrated a promising effectiveness and acceptable toxicity in patients with advanced NSCLC, even in patients older than 75 years. ...
  8. ncbi request reprint Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Surg 76:1810-4; discussion 1815. 2003
    ..We performed a phase II trial using this chemoradiotherapy as an induction treatment...
  9. doi request reprint Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy
    Yukito Ichinose
    National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 40:521-9. 2010
    ....
  10. ncbi request reprint A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical inter
    Yukito Ichinose
    National Kyushu Cancer Center, Fukuoka National Cancer Center Hospital, Tokyo, Japan
    J Thorac Cardiovasc Surg 123:695-9. 2002
    ....
  11. ncbi request reprint Diagnosis of visceral pleural invasion in resected lung cancer using a jet stream of saline solution
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Surg 64:1626-9. 1997
    ..Visceral pleural invasion by the tumor is an important prognostic factor in patients undergoing resection for lung cancer. We developed a method to detect more accurately the presence of visceral pleural invasion in resected lung cancer...
  12. ncbi request reprint Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease
    Y Ichinose
    National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka 811 1395, Japan
    Lung Cancer 32:55-60. 2001
    ....
  13. ncbi request reprint Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    J Surg Oncol 66:196-200. 1997
    ..In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated...
  14. ncbi request reprint Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials
    Y Ichinose
    National Kyushu Cancer Center, Fukuoka, Japan
    Lung Cancer 34:29-36. 2001
    ..multiple N2 stations) was found to be a useful prognostic factor, which can separate completely resected stage IIIA-N2 patients into high and low risk groups regarding both the overall survival and local recurrence...
  15. ncbi request reprint Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    J Surg Oncol 46:15-20. 1991
    ..Furthermore, analysis of postrecurrent survival in the adjuvant chemotherapy trial, as well as that of overall and disease-free survivals should be done...
  16. ncbi request reprint Prognosis of non-small cell lung cancer patients with positive pleural lavage cytology after a thoracotomy: results of the survey conducted by the Japan Clinical Oncology Group
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Notame, Minami-ku, 811-1395, Fukuoka, Japan
    Lung Cancer 31:37-41. 2001
    ..CONCLUSION: Patients with a positive pleural lavage cytology in pathological stage I or II appear to have a poor 5-year survival rate...
  17. ncbi request reprint A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Harubumi Kato
    Department of Surgery, Tokyo Medical University, Tokyo, Japan
    N Engl J Med 350:1713-21. 2004
    ..A subgroup analysis disclosed that most patients who benefited had pathological stage I adenocarcinoma...
  18. ncbi request reprint [Postoperative adjuvant chemotherapy for non-small cell lung cancer]
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Gan To Kagaku Ryoho 32:765-9. 2005
    ..This review evaluated the role of adjuvant chemotherapy, based on the results of randomized trials and meta-analyses...
  19. ncbi request reprint A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)
    Kanji Nagai
    Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
    J Thorac Cardiovasc Surg 125:254-60. 2003
    ..We performed a prospective randomized trial in patients with potentially resectable stage IIIA N2 non-small cell lung cancer to confirm the efficacy of induction chemotherapy before surgical resection...
  20. ncbi request reprint S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1, Notame, Minami ku Fukuoka, Japan
    Clin Cancer Res 10:7860-4. 2004
    ....
  21. ncbi request reprint Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station
    Y Ichinose
    National Kyushu Cancer Center, Fukuoka, Japan
    J Thorac Cardiovasc Surg 122:803-8. 2001
    ..The number of N2 stations is a good prognosticator except in patients with a primary tumor in the left lower lobe. In addition, the site of a primary tumor itself is also considered to influence the survival of the patients...
  22. ncbi request reprint Chemotherapy for advanced non-small cell lung cancer
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    Natl Med J India 9:24-5. 1996
    ..The authors concluded that oral uracil and tegafur were as effective as other combinations with cisplatin. They also caused very few side-effects. They suggest that a larger trial needs to be carried out...
  23. ncbi request reprint Lung cancer in patients younger than 40 years of age
    R Maruyama
    Department of Chest Surgery, National Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan
    J Surg Oncol 77:208-12. 2001
    ..0615). CONCLUSIONS: This study suggests that the prognosis of young patients with lung cancer is at least equivalent to that of older patients; therefore, they should be managed according to the general therapeutic guidelines...
  24. ncbi request reprint [Current status of the neo-adjuvant and adjuvant therapy for the resectable non-small cell lung cancer]
    Masafumi Yamaguchi
    Dept of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Gan To Kagaku Ryoho 30:203-8. 2003
    ..Further assessment for the well designed phase III clinical trials will be necessary to establish the availability of such modalities for the treatment of respectable NSCLC...
  25. ncbi request reprint Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs
    I Yoshino
    Department of Chest Surgery, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan
    Ann Thorac Cardiovasc Surg 7:204-9. 2001
    ..CONCLUSIONS: Patients even with recurrence in distant organs could expect for long survival if they are in the early p-stage of primary cancer or a resectable recurrent disease...
  26. doi request reprint Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel
    I Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 20:1483-8. 2009
    ..This report describes quality of life (QoL) findings of a randomized study comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated non-small-cell lung cancer...
  27. ncbi request reprint Necessity of preoperative screening for brain metastasis in non-small cell lung cancer patients without lymph node metastasis
    Tomofumi Yohena
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Cardiovasc Surg 10:347-9. 2004
    ..However, a routine examination using magnetic resonance imaging (MRI) for the brain remains controversial in preoperative patients with resectable disease...
  28. ncbi request reprint [Postoperative adjuvant treatment for non-small cell lung cancer]
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Gan To Kagaku Ryoho 29:2470-4. 2002
    ..Many phase III trials with chemotherapy, radiotherapy, chemoradiotherapy or other modalities as postoperative adjuvant treatment have been conducted. However, no adjuvant treatment has been established as a result of those trials...
  29. ncbi request reprint Distribution of hematoporphyrin derivative in normal and malignant tissue
    N Hara
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    Jpn J Exp Med 58:139-43. 1988
    ..Our data were different from those that suggested the selectivity of uptake and retention of HpD by malignant tissues, using fluorometric techniques...
  30. ncbi request reprint Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Anticancer Res 29:4217-21. 2009
    ..The optimal treatment for patients with progressive non-small cell lung cancer who initially show a good response to gefitinib is unclear...
  31. doi request reprint Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study
    Shoji Kudoh
    Nippon Medical School, Tokyo, Japan
    Am J Respir Crit Care Med 177:1348-57. 2008
    ..Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib...
  32. ncbi request reprint Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Oncology 70:325-9. 2006
    ..The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC)...
  33. ncbi request reprint Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer
    Jiro Ikeda
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 36:12-6. 2006
    ....
  34. ncbi request reprint Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer
    Masahiro Tsuboi
    Tokyo Medical University Hospital, Tokyo, Japan
    Anticancer Drugs 16:1123-8. 2005
    ..In the adjuvant setting there were no unexpected adverse events observed. Gefitinib had no impact on surgery-related complications when given within 4-6 weeks post-operatively...
  35. ncbi request reprint Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy
    Koji Yamazaki
    Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    Anticancer Res 30:1311-5. 2010
    ....
  36. ncbi request reprint Triplet chemotherapy for malignant pericardial mesothelioma: a case report
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 36:245-8. 2006
    ..The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression...
  37. ncbi request reprint Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer
    Takashi Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Lung Cancer 53:91-6. 2006
    ..Angiogenesis plays an important role in tumorigenesis and has attracted interest as a potential target in cancer treatment...
  38. doi request reprint Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502
    Takashi Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka, 811 1395, Japan
    Lung Cancer 69:213-7. 2010
    ..TS-1 with gemcitabine is a promising doublet regimen in elderly patients with advanced NSCLC with acceptable toxicities...
  39. doi request reprint Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    Riichiroh Maruyama
    National Kyushu Cancer Center, Fukuoka, Japan
    J Clin Oncol 26:4244-52. 2008
    ..This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) with advanced/metastatic non-small-cell lung cancer (NSCLC) who had failed one or two chemotherapy regimens...
  40. doi request reprint Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum
    Takashi Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Thorac Oncol 3:637-42. 2008
    ....
  41. ncbi request reprint Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial
    Riichiroh Maruyama
    Kyushu Yamaguchi Thoracic Oncology Group, Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    J Thorac Oncol 2:65-8. 2007
    ..The effect of pericardial drainage and the intra-pericardial instillation of bleomycin on the control of MPE was examined in this prospective multi-institutional phase II trial...
  42. ncbi request reprint Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Lung Cancer 56:449-53. 2007
    ....
  43. ncbi request reprint Establishment of a clinical pathway as an effective tool to reduce hospitalization and charges after video-assisted thoracoscopic pulmonary resection
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Jpn J Thorac Cardiovasc Surg 54:387-90. 2006
    ..The purpose of this study was to assess the effect of establishing a clinical pathway based on the length of hospitalization, hospital charges, and the outcome for video-assisted thoracoscopic pulmonary resection (VATPR)...
  44. ncbi request reprint Initial experience with video-assisted thoracoscopic surgery for pulmonary metastasis in the prone position
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Surg Laparosc Endosc Percutan Tech 16:117-8. 2006
    ..In cases where the lateral decubitus position cannot be used, the prone position is both safe and effective for treating dorsal lesions of the lung by means of video-assisted thoracoscopic surgery...
  45. ncbi request reprint [Randomized controlled trials in Japan--lung cancer]
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Gan To Kagaku Ryoho 29:1516-21. 2002
    ..No adjuvant treatment method for resected patients has been proved to be sufficiently effective...
  46. ncbi request reprint Prognostic value of visceral pleural invasion in resected non-small cell lung cancer diagnosed by using a jet stream of saline solution
    Riichiroh Maruyama
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Thorac Cardiovasc Surg 127:1587-92. 2004
    ....
  47. ncbi request reprint Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Jpn J Clin Oncol 35:433-8. 2005
    ..We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM...
  48. ncbi request reprint Clinical patterns and treatment outcome of elderly patients in clinical stage IB/II non-small cell lung cancer
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    J Surg Oncol 87:134-8. 2004
    ..To better manage such elderly patients, the clinical characteristics and prognosis of patients with these stages, who were 75 years of age or older, were reviewed...
  49. ncbi request reprint Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1 Notame, Fukuoka 811 1395, Japan
    Eur J Cancer 41:1286-90. 2005
    ..These data show that the serum CEA level can be a predictive factor for the efficacy of gefitinib treatment while it is also a prognostic factor for advanced NSCLC patients undergoing this treatment...
  50. ncbi request reprint Long-term survivors in stage IV non-small cell lung cancer
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1, Notame, Minami Ku, Fukuoka 811 1395, Japan
    Lung Cancer 47:85-91. 2005
    ..To determine the prognostic factors for long-term survivors (LTS) with stage IV non-small cell lung cancer (NSCLC) who had undergone various treatments...
  51. ncbi request reprint Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation
    Ichiro Yoshino
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Thorac Oncol 1:825-31. 2006
    ..In clinical stage IA lung adenocarcinoma, the clinical features of a truly node-negative population were prospectively investigated by means of a prospective investigational study...
  52. doi request reprint Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib
    Hiroshi Wataya
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame 3 1 1, Minami Ku, Fukuoka 811 1395, Japan
    Lung Cancer 64:341-5. 2009
    ..The effectiveness of the first-line chemotherapy was therefore found to be a prognostic factor in the gefitinib responders with previously treated NSCLC, while the PS was shown to be a prognostic factor in the gefitinib non-responders...
  53. ncbi request reprint [Preoperative and postoperative radiotherapy for lung cancer]
    Yukito Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center
    Nihon Rinsho 60:446-9. 2002
  54. ncbi request reprint Treatment outcome of resected and nonresected primary adenoid cystic carcinoma of the lung
    Takanori Kanematsu
    Department of Chest Surgery, National Kyushu Cancer Center, Minami Ku, Japan
    Ann Thorac Cardiovasc Surg 8:74-7. 2002
    ..The incidence of primary adenoid cystic carcinoma of the lung is relatively rare and the optimal treatment strategy is still unclear...
  55. ncbi request reprint [Reevaluation of the surgical indications for non-small cell lung cancer based on the results of postoperative treatment]
    Y Ichinose
    Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan
    Nippon Geka Gakkai Zasshi 102:541-5. 2001
    ..Therefore clinical trials should be conducted to determine the most appropriate postoperative regimen in NSCLC...
  56. pmc Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis
    S Kuninaka
    Clinical Research Institute, Department of Chest Surgery, Gastroenterologic Surgery, National Kyushu Cancer Center, Notame 3 1 1, Minami Ku, Fukuoka, 811 1395, Japan
    Br J Cancer 83:928-34. 2000
    ..Therefore, we suggest that Mn-SOD could be a target molecule to overcome the resistance to anti-cancer treatments in some colon cancer cells carrying wild-type p53...
  57. doi request reprint Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution
    Tetsuzo Tagawa
    Department of Thoracic Oncology, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    J Surg Oncol 101:495-9. 2010
    ..We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC)...
  58. ncbi request reprint The use of a water seal to manage air leaks after a pulmonary lobectomy: a retrospective study
    Junichi Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Cardiovasc Surg 12:242-4. 2006
    ..The methods for managing chest drainage tubes during the postoperative period differ among thoracic surgeons and, as a result, the optimal method remains controversial...
  59. ncbi request reprint Incidentally proven pulmonary "ALKoma"
    Atsushi Osoegawa
    Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
    Intern Med 49:603-6. 2010
    ..The commercial-based ALK FISH is useful for screening pulmonary ALKoma...
  60. ncbi request reprint A long-term survivor after aggressive treatment for tracheal adenoid cystic carcinoma: a case report
    Ryuichi Suemitsu
    Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Cardiovasc Surg 13:335-7. 2007
    ..Although the patient had five instances of recurrence over an 11-year period during his treatment course, he is presently doing well as a result of appropriate local treatments using multiple modalities...
  61. ncbi request reprint Hepatic lesion of invasive thymoma: possibility of direct invasion
    Tatsuro Okamoto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame 3 1 1, Minami Ku, Fukuoka, 811 1395, Japan
    Int J Clin Oncol 12:300-2. 2007
    ..Appropriate local control in the early stages of the clinical course may therefore be essential for preventing the extrathoracic spread of invasive thymoma...
  62. ncbi request reprint [Treatment of double cancers including lung cancer]
    Chie Ushijima
    Department of Chest Surgery, National Kyushu Cancer Center
    Nihon Rinsho 60:532-5. 2002
  63. ncbi request reprint Thoracic malignant peripheral nerve sheath tumour mimicking a pleural tumour: a rare pedunculated appearance
    Masahiro Komori
    Department of Radiology, National Kyushu Cancer Centre, 3 1 1 Notame, Minami Ku, Fukuoka 811 1395, Japan
    Pediatr Radiol 33:578-81. 2003
    ..In this report, we present the CT and MRI findings of our case, together with the histopathological findings, and review previous reports...
  64. ncbi request reprint Methodological aspects of current problems in target-based anticancer drug development
    Takeharu Yamanaka
    Cancer Statistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
    Int J Clin Oncol 11:167-75. 2006
    ..Precise and efficient detection of responder populations is the key to the development and establishment of target-based anticancer therapies...
  65. ncbi request reprint Intrathoracic omental herniation through the esophageal hiatus in a young patient
    Riichiroh Maruyama
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Jpn J Thorac Cardiovasc Surg 53:452-4. 2005
    ..This is the first report of omental herniation through the esophageal hiatus in a patient still in his twenties...
  66. ncbi request reprint Wide sleeve resection of lower trachea through anterior approach with omentopexy
    Ichiro Yoshino
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Asian Cardiovasc Thorac Ann 14:66-8. 2006
    ..5 cm (case 1) and 4.0 cm (case 2) in length. Both patients had an uneventful course after surgery despite postoperative irradiation in case 1 and preoperative infection with methicillin-resistant Staphylococcus aureus in case 2...
  67. ncbi request reprint Pulmonary typical carcinoid tumor and liver metastasis with hypermetabolism on 18-fluorodeoxyglucose PET: a case report
    Ryuichi Suemitsu
    Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan
    Ann Thorac Cardiovasc Surg 14:109-11. 2008
    ..Thereafter he underwent partial resection of he liver mass, and the histology was metastasis from pulmonary carcinoid. We first reported a typical pulmonary carcinoid that showed high FDG uptake at the primary site and liver metastasis...
  68. ncbi request reprint Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)
    Ryosuke Tsuchiya
    Division of Thoracic Surgery, National Cancer Center Hospital, 1 1 Tsukiji 5 cho me, Chuo Ku, Tokyo 104 0045, Japan
    J Thorac Cardiovasc Surg 129:977-83. 2005
    ..Indications for surgical intervention for very limited small cell lung cancer have not yet been determined. The objective of this study is to determine whether resection followed by cisplatin and etoposide is feasible...
  69. ncbi request reprint Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
    Miguel Taron
    Catalan Institute of Oncology, Pathology Department, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 11:5878-85. 2005
    ..Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) confer a strong sensitivity to gefitinib, a selective tyrosine kinase inhibitor of EGFR...
  70. ncbi request reprint [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]
    Hiroshi Wataya
    Dept of Thoracic Oncology, National Kyushu Cancer Center
    Gan To Kagaku Ryoho 33:501-3. 2006
    ..Survival time was 709 days. This combination chemotherapy was effective in the present case, and might prolong survival. We think it is valuable to confirm the efficacy of TS-1 and cisplatin combination chemotherapy...
  71. ncbi request reprint A prospective Japanese study of the association between personality and the progression of lung cancer
    Jun Nagano
    Institute of Health Science, Kyushu University, Fukuoka
    Intern Med 45:57-63. 2006
    ....
  72. ncbi request reprint Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Badalona Barcelona, Spain
    Lung Cancer 50:25-33. 2005
    ..The presence of EGFR mutations is a major determinant of gefitinib response, and EGFR tyrosine kinase inhibitors should be tested in clinical trials of first-line treatment of lung adenocarcinomas harboring EGFR mutations...
  73. ncbi request reprint [Radiotherapy for aged patients with non-small cell lung cancer]
    Hideki Hirata
    Department of Radiotherapy, National Kyushu Cancer Center
    Nihon Rinsho 60:596-9. 2002
  74. ncbi request reprint Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902
    Hiroshi Saito
    Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki Aichi, Japan
    J Clin Oncol 24:5247-52. 2006
    ..We amended the protocol to evaluate IP after EP with concurrent twice-daily TRT in a single-arm phase II study because of an unacceptable toxicity in IPE...
  75. ncbi request reprint [Management of adverse events in lung cancer treatment in octogenarians]
    Yasuro Fukuyama
    Department of Thracic Oncology, National Kyushu Cancer Center
    Nihon Rinsho 60:600-2. 2002
  76. doi request reprint Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Clin Cancer Res 14:4206-12. 2008
    ..The objective of this study was to evaluate the efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B(12) in pretreated Japanese patients with advanced non-small cell lung cancer (NSCLC)...
  77. ncbi request reprint [Adjuvant chemotherapy for non-small cell lung cancer]
    Tatsuro Okamoto
    Dept of Thoracic Oncology, National Kyushu Cancer Center
    Gan To Kagaku Ryoho 33:1985-90. 2006
    ..We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC...
  78. doi request reprint Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients
    Kazuhiko Nakagawa
    Kinki University School of Medicine, Medical Oncology, 377 2 Ohnohigashi, Osakasayama 589 8511, Japan
    Jpn J Clin Oncol 38:339-46. 2008
    ..This Phase I/II study was conducted to determine the recommended dose (RD) (Phase I) of Pem/Cis, and evaluate the efficacy and safety (Phase II) in Japanese MPM patients...
  79. ncbi request reprint [A case of preoperative concurrent chemoradiotherapy and curative resection for locally advanced non-small-cell lung cancer]
    Takao Teruya
    Dept of Chest Surgery, National Kyushu Cancer Center
    Gan To Kagaku Ryoho 29:1791-4. 2002
    ..The patient underwent complete resection and a pathologic complete response was observed. This induction concurrent chemoradiotherapy (followed by surgery) is considered to be effective and safe...
  80. doi request reprint Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501
    Riichiroh Maruyama
    Department of Surgery, Nippon Steel Yawata Memorial Hospital, 1 1 1 Harunomachi, Yahatahigashi ku, Kitakyushu 805 8508, Japan
    Gen Thorac Cardiovasc Surg 56:68-73. 2008
    ....
  81. ncbi request reprint A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304)
    Hirohito Tada
    Division of General Thoracic Surgery, Osaka City General Hospital, 2 13 22 Miyakojima Hondori, Miyakojima ku, Osaka 534 0004, Japan
    Lung Cancer 43:167-73. 2004
    ..Postoperative cisplatin with vindesine chemotherapy was not shown to be efficacious in cases of completely resected N2 non-small cell lung cancer in this setting of timing, dose and agents studied...
  82. ncbi request reprint Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group
    Kaoru Kubota
    Thoracic Oncology Division, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    J Clin Oncol 22:254-61. 2004
    ..The primary aim of this study was to test whether docetaxel plus cisplatin (DC) improves survival compared with vindesine plus cisplatin (VdsC) in patients with previously untreated stage IV NSCLC...